CURE Pharmaceutical Holding Corp. (CURR) financial statements (2021 and earlier)

Company profile

Business Address 1620 BEACON PLACE
OXNARD, CA 93033
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments241010
Cash and cash equivalents241010
Receivables00000 
Inventory, net of allowances, customer advances and progress billings000000
Inventory000000
Prepaid expense 01100
Deferred costs 1    
Other undisclosed current assets11    
Total current assets:462110
Noncurrent Assets
Finance lease, right-of-use asset00
Operating lease, right-of-use asset00
Property, plant and equipment210000
Intangible assets, net (including goodwill)1611111 
Goodwill149    
Intangible assets, net (excluding goodwill)22111 
Deferred costs   0  
Other undisclosed noncurrent assets2415000 
Total noncurrent assets:43262110
TOTAL ASSETS:46323230
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31110 
Accounts payable21110 
Accrued liabilities10100 
Employee-related liabilities0     
Taxes payable0     
Debt101200
Asset retirement obligation    (0) 
Due to related parties1     
Other undisclosed current liabilities910610 
Total current liabilities:14129410
Noncurrent Liabilities
Long-term debt and lease obligation70    
Long-term debt, excluding current maturities7     
Finance lease, liability 0
Other undisclosed noncurrent liabilities47 11 
Total noncurrent liabilities:117 11 
Total liabilities:25199410
Stockholders' equity
Stockholders' equity attributable to parent, including:2114(5)(2)20
Common stock000000
Additional paid in capital102632316120
Accumulated deficit(81)(51)(29)(19)(11)(0)
Other undisclosed stockholders' equity attributable to parent1110  
Stockholders' equity attributable to noncontrolling interest  00  
Total stockholders' equity:2114(5)(2)20
TOTAL LIABILITIES AND EQUITY:46323230

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
Revenues211000
Revenue, net000
Cost of revenue(1)(0)(0)(0)(0)(0)
Cost of goods and services sold  (0)(0)(0)(0)
Deferred policy acquisition costs, amortization expense (0)    
Other undisclosed gross profit     (0)
Gross profit:100(0)(0)0
Operating expenses(20)(14)(8)  (0)
Other undisclosed operating loss   (7)(4) 
Operating loss:(19)(14)(8)(7)(4)(0)
Nonoperating expense(11)(8)(3)(1)(0) 
Other nonoperating expense(12)(8)(3)(1)(0) 
Interest and debt expense(0)4(3)(2)(0) 
Loss from continuing operations before equity method investments, income taxes:(30)(18)(13)(10)(4)(0)
Income from equity method investments0     
Other undisclosed income (loss) from continuing operations before income taxes(0)(4)320 
Loss from continuing operations before income taxes:(31)(21)(10)(8)(4)(0)
Other undisclosed loss from continuing operations (0)    
Loss before gain (loss) on sale of properties:(31)(21)(10)(8)(4)(0)
Other undisclosed net income 0    
Net loss:(31)(21)(10)(8)(4)(0)
Net income attributable to noncontrolling interest 2100  
Other undisclosed net loss attributable to parent (21)(0)   
Net loss attributable to parent:(31)(21)(10)(8)(4)(0)
Other undisclosed net income available to common stockholders, basic  0   
Net loss available to common stockholders, diluted:(31)(21)(10)(8)(4)(0)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
Net loss:(31)(21)(10)(8)(4)(0)
Comprehensive loss:(31)(21)(10)(8)(4)(0)
Comprehensive income, net of tax, attributable to noncontrolling interest 2100  
Comprehensive income (loss), net of tax, attributable to parent:(31)0(10)(8)(4)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: